Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds - 213 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- 3The Best Computer games for Multiplayer Fun
- 4Expert advice for new stargazers: How to begin your amateur astronomy journey
- 5Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- Winter storms blanket the East, while the U.S. West is wondering: Where’s the snow?
- Israel reports killing another senior Iranian oil official
- Europe’s Airlines Run Low on Fuel
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Knesset sets special panel to fast-track Karhi’s communications reform
- Illumina unveils dataset to speed up AI-powered drug discovery
- The Meaning of Breaking the Pen's Nib in Death penalties
- This Overlooked Predator Is Running Out of Time—Why Conservationists Are Racing to Save the Striped Hyena
- Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby.
